Monday, December 8, 2025

After More Than 35 Years at the Company: Vetter Bids Farewell to Managing Director Thomas Otto – Strategic Succession Ensures Continuity

Vetter has announced a major leadership transition: Managing Director Thomas Otto will retire at the end of 2025 after more than 35 years with the company. The globally leading CDMO marks the end of an era defined by sustainable growth, clear leadership and consistent international expansion.

For more than two decades on the Management Board, Otto played a decisive role in shaping the company’s strategic direction. His vision, strong sense of responsibility and close collaboration with global biopharmaceutical partners helped position Vetter as a reliable provider of high-quality development and manufacturing services.

Senator h.c. Udo J. Vetter, Chairman of the Advisory Board, emphasized the exceptional impact of the outgoing Managing Director: his innovative strength, drive and role as a bridge builder have significantly shaped the company.

Otto himself reflects positively on his long tenure. He expressed gratitude for the trustful cooperation and the opportunity to help prepare Vetter for the future. Looking ahead, he will continue to support the company in an advisory role, particularly regarding the development of a new production facility in Germany.

In parallel with his retirement announcement, Vetter highlights the importance of a proactive succession strategy. At the beginning of 2025, the experienced executives Henryk Badack, Titus Ottinger and Carsten Press were appointed Managing Directors. With extensive industry expertise and a deep understanding of Vetter’s culture, customer relationships and global market requirements, they are well positioned to lead the organization forward.

With this structured leadership transition, Vetter sends a clear signal of stability and sustainable development. The company remains a trusted partner for customers, employees and the region. Through close collaboration with global biopharmaceutical companies, Vetter continues to play an essential role in ensuring that life-enhancing medicines reach patients worldwide.